Top Markets
Coin of the day
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd.

GLMD
Peringkat dalam Saham #35178
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the... Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Harga Saham
$0.5225
Terakhir disinkronkan: 2026-08-14
Kapitalisasi Pasar
$4.32M
Perubahan (1 hari)
-1.60%
Perubahan (1 tahun)
-63.72%
Negara
IL
Perdagangan Galmed Pharmaceuticals Ltd. (GLMD)

Kategori

Rasio P/S untuk Galmed Pharmaceuticals Ltd. (GLMD)
Rasio P/S per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari Galmed Pharmaceuticals Ltd., rasio P/S saat ini (TTM) adalah 0. Pada akhir 2026, rasio P/S perusahaan adalah 0.
Riwayat rasio P/S untuk Galmed Pharmaceuticals Ltd. dari 2026 hingga 2026
Rasio P/S pada akhir setiap tahun
Tahun Rasio P/S Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Rasio P/S untuk perusahaan sejenis atau pesaing
Perusahaan Rasio P/S Perbedaan Rasio P/S Negara
10.17 -
US
10.13 -
NL
- -
CH
- -
KR
4.74 -
BE